Editas Medicine, Inc.
EDIT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $32 | $78 | $20 | $26 |
| % Growth | -58.6% | 296.3% | -22.8% | – |
| Cost of Goods Sold | $0 | $6 | $6 | $5 |
| Gross Profit | $32 | $72 | $13 | $20 |
| % Margin | 100% | 92.2% | 67.9% | 80.2% |
| R&D Expenses | $199 | $178 | $175 | $143 |
| G&A Expenses | $72 | $70 | $71 | $76 |
| SG&A Expenses | $72 | $70 | $71 | $76 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $12 | -$6 | -$6 | -$5 |
| Operating Expenses | $283 | $241 | $239 | $214 |
| Operating Income | -$251 | -$169 | -$226 | -$193 |
| % Margin | -777.2% | -216.6% | -1,146.3% | -756.1% |
| Other Income/Exp. Net | $14 | $16 | $6 | $1 |
| Pre-Tax Income | -$237 | -$153 | -$220 | -$193 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$237 | -$153 | -$220 | -$193 |
| % Margin | -733.7% | -196.1% | -1,118.3% | -753.6% |
| EPS | -2.88 | -2.02 | -3.21 | -2.85 |
| % Growth | -42.6% | 37.1% | -12.6% | – |
| EPS Diluted | -2.88 | -2.02 | -3.21 | -2.85 |
| Weighted Avg Shares Out | 82 | 76 | 69 | 68 |
| Weighted Avg Shares Out Dil | 82 | 76 | 69 | 68 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $18 | $6 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6 | $6 | $6 | $5 |
| EBITDA | -$233 | -$163 | -$220 | -$188 |
| % Margin | -721.4% | -208.8% | -1,114.1% | -736.3% |